Eltrombopag Added to Immunosuppression in Severe Aplastic Anemia
Université Paris Cité · Saint Louis University Hospital · +30 more institutions
Abstract
A single-group, phase 1-2 study indicated that eltrombopag improved the efficacy of standard immunosuppressive therapy that entailed horse antithymocyte globulin (ATG) plus cyclosporine in patients with severe aplastic anemia.
In this prospective, investigator-led, open-label, multicenter, randomized, phase 3 trial, we compared the efficacy and safety of horse ATG plus cyclosporine with or without eltrombopag as front-line therapy in previously untreated patients with severe aplastic anemia. The primary end point was a hematologic complete response at 3 months.
Citation impact
- FWCI
- 40.44
- Percentile
- 100%
- References
- 32
Authors
50- RPRégis Peffault de LatourCorresponding
Université Paris Cité, Saint Louis University Hospital, Centre Hospitalier Universitaire de Toulouse, European Society for Blood and Marrow Transplantation
- AKAustin Kulasekararaj
Centre Hospitalier Universitaire de Toulouse, European Society for Blood and Marrow Transplantation, King's College Hospital NHS Foundation Trust
- SISimona Iacobelli
University of Rome Tor Vergata, Centre Hospitalier Universitaire de Toulouse, European Society for Blood and Marrow Transplantation
- STSofie Terwel
Centre Hospitalier Universitaire de Toulouse, European Society for Blood and Marrow Transplantation
- RCRiley Cook
Centre Hospitalier Universitaire de Toulouse, King's College Hospital NHS Foundation Trust
Topics & keywords
- Eltrombopag
- Medicine
- Aplastic anemia
- Internal medicine
- Gastroenterology
- Clinical endpoint
- Group B
- Randomized controlled trial
- Good health and well-being